RecruitingNCT05506293

European Multicentre Registry of Percutaneous Paravalvular Leak Closure

European Multicentre Registry of Percutaneous Paravalvular Leak Closure - EuroPVL Study


Sponsor

Centre Chirurgical Marie Lannelongue

Enrollment

400 participants

Start Date

Jan 1, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

Paraprosthetic cardiac valve leaks are a progressive complication after after surgical or percutaneous heart valve replacement. These leaks can lead to heart failure and/or life-threatening hemolysis. Percutaneous closure of para-prosthetic leaks has been developed as an alternative to surgery in high-risk patients. These procedures remain technically challenging with a significant risk of failure and complications, but this risk is improved since the development of dedicated prostheses and the increased experience of the operators. The data in the literature concerning percutaneous leak closure remain limited and disparate and mostly retrospective.The impact of the procedures on the quality of life of patients is not known. Beyond the technical aspects and the follow-up of major cardiovascular events, investigators also wonder what is the impact of these procedures on the quality of life of patients. Investigators hypothesize that even a partial reduction in paraprosthetic leakage may be associated with an improvement in quality of life through reduction of transfusion needs and/or reduction of dyspnea. A prospective study is warranted to assess the technical and clinical and clinical results of these procedures, together with the evaluation of the the possible benefit on the quality of life of the patients.


Eligibility

Min Age: 16 YearsMax Age: 110 Years

Inclusion Criteria1

  • ≥16 years of age No opposition from the patient or the representative of the parental authority if the patient is a minor Patient referred for a percutaneous paraprosthetic leak closure procedure

Exclusion Criteria1

  • \< 16 years old Refusal of the patient to participate in the observatory or of the legal representative if the patient is a minor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREpercutaneous paravalvular leak closure

the procedure consists of deployment of an occluder or a vascular plug within the cardiac paravalvular leak. The device is inserted percutaneously from a femoral vascular approach or from a trans-apical approach. The device is deployed through a delivery sheath within the leak. Stability and efficacy to occlude the leak are assessed by transoesophageal echocardiography prior to device release. Type of devices to be inserted varied : * Amplatzer vascular plug 3 * occlutech paravalvular leak device * amplatzer vascular plug 2 * amplatzer muscular ventricular septal defect * amplatzer vascular plug 4 Devices to be implanted are under the responsability of the local investigator and are not based on the study design.


Locations(33)

CHU Charleroi

Charleroi, Belgium

Podlesi hospital

Třinec, Czechia

CHU Amiens

Amiens, France

Hopital d Annecy

Annecy, France

CHU Henri Mondor

Créteil, France

CHU Grenoble

Grenoble, France

centre chirurgical Marie Lannelongue

Le Plessis-Robinson, France

Hopital Prive Brabois

Lille, France

CHU La Timone

Marseille, France

Hopital Europeen

Marseille, France

Hopital Prive Clairval

Marseille, France

CHU Nancy

Nancy, France

Hopital prive les Franciscaines

Nîmes, France

HEGP

Paris, France

Hopital Bichat

Paris, France

Hopital Pitie Salpetriere

Paris, France

CHU Rennes

Rennes, France

Hopital Charles Nicolle

Rouen, France

Centre Cardiologique du Nord

Saint-Denis, France

institut Arnault Tzanck

Saint-Laurent-du-Var, France

CHU Toulouse

Toulouse, France

Clinique Pasteur

Toulouse, France

Medipole Lyon Villeurbanne

Villeurbanne, France

National and kapodistrian university of athens

Athens, Greece

University School of Milan

Milan, Italy

Pauls Stradins Clinical University Hospital

Riga, Latvia

Vilnius University Hospital

Vilnius, Lithuania

hospital infantil de Mexico Frederico Gomez

Mexico City, Mexico

Medical University of Silesia

Katowice, Poland

Hospital Clinic of Barcelona

Barcelona, Spain

Kocaeli University Medical Faculty

Kocaeli, Turkey (Türkiye)

Royal Papworth hospital

Cambridge, United Kingdom

Edinburgh Royal Infirmary

Edinburgh, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05506293


Related Trials